Welcome to our dedicated page for Bunge Global SA SEC filings (Ticker: BG), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Bunge Global SA filings document the regulatory record of a Swiss-incorporated agribusiness company with registered shares listed on the New York Stock Exchange under BG. Its disclosures cover operating and financial results, material events, proxy governance, shareholder voting matters and capital-structure changes.
The company's recent 8-K filings include amendments to a trade receivables securitization program, executive compensation arrangements tied to integration efforts, amendments to its Articles of Association following share cancellations, and exhibits for results releases. Proxy materials address board governance, voting matters, executive compensation and other shareholder disclosures, while material-event reports also document integration and risk-related information following completed acquisitions.
Bunge Global SA director reported a small equity award from the company. On December 1, 2025, the reporting person acquired 18 shares of common stock in the form of restricted stock units pursuant to a dividend feature under Bunge Global SA's long-term incentive plans at a reference price of $96.47 per share. Following this transaction, the director beneficially owned 29,584 shares of common stock, held directly.
Bunge Global SA director reported acquiring additional common shares through the company’s long-term incentive plans. On December 1, 2025, the reporting person received 18 restricted stock units pursuant to a dividend feature, effectively reinvesting dividends into stock-based awards at a price of $96.47 per share. Following this transaction, the reporting person beneficially owned 6,543 shares of Bunge Global SA common stock in direct ownership.
Bunge Global SA reported a routine insider equity transaction for its Co-Chief Operating Officer. On 12/01/2025, the executive acquired 283 restricted stock units of Bunge Global SA common stock at a reference price of $96.47 per share under a dividend feature of the company’s long-term incentive plans. After this transaction, the reporting person beneficially owned a total of 124,127.321 shares of Bunge Global SA common stock in direct ownership form. This filing is an administrative update of equity compensation rather than a major corporate event.
Bunge Global SA director reported a routine equity grant in the form of restricted stock units. On 12/01/2025, the insider acquired 15 shares of Common Stock at a price of $96.47 per share, recorded under the company’s long-term incentive plans. The transaction increased the director’s holdings to 2,197 shares of Bunge Global SA common stock held directly.
Bunge Global SA reported that one of its directors acquired additional equity on December 1, 2025. The director received 18 restricted stock units of Bunge Global SA common stock as a result of a dividend feature under the company’s long-term incentive plans, rather than through an open-market purchase.
The transaction is coded as an acquisition at a reference price of $96.47 per share. Following this award, the reporting person beneficially owns a total of 33,441.7968 shares of Bunge Global SA common stock in direct ownership form.
Bunge Global SA reported a small insider equity award for one of its directors. On December 1, 2025, the director acquired 15 shares of common stock at a price of $96.47 per share. The filing explains that these shares represent restricted stock units granted on that date under a dividend feature in Bunge Global’s long-term incentive plans, meaning the award reflects dividends credited in stock rather than cash. After this transaction, the director beneficially owns 2,197 shares of Bunge Global common stock directly.
Bunge Global SA director reported a small equity award under the company’s long-term incentive plans. On December 1, 2025, the reporting person acquired 18 shares of common stock at a price of $96.47 per share through restricted stock units credited via a dividend feature. After this transaction, the director beneficially owned 8,783 shares directly. This filing reflects routine equity-based compensation rather than an open-market purchase or sale.
Bunge Global SA director reported a small equity award related to their existing holdings. On 12/01/2025, the insider acquired 15 shares of common stock at $96.47 per share through restricted stock units credited under a dividend feature in the company's long-term incentive plans. Following this routine transaction, the reporting person beneficially owned 7,197 shares directly. This reflects ongoing participation in Bunge's equity-based compensation and dividend programs rather than an open-market purchase or sale.
Bunge Global SA director reports a small equity award. A company director acquired 34 shares of Bunge Global SA common stock on December 1, 2025 as restricted stock units with a value reference of $96.47 per share, granted under the company’s long-term incentive plans through a dividend feature. After this transaction, the director beneficially owns 21,871 shares directly and 6,500 shares indirectly through the Zenuk Family Living Trust u/a/d 09/01/2015.
Bunge Global SA (BG) reported an insider transaction by its Executive VP, Global Markets. On 11/21/2025, the officer exercised stock options to acquire 5,300 shares of common stock at an exercise price of $50.07 per share and then sold shares on the same day.
The reported sales included 5,300 shares of common stock at a weighted average price of $94.3823 per share (from trades between $94.30 and $94.48) and an additional 20,000 shares at a weighted average price of $94.3709 per share (from trades between $94.28 and $94.44). After these transactions, the officer beneficially owned 104,536.808 shares of Bunge Global SA common stock directly.
The derivative position reported was a stock option (right to buy) for 5,300 shares at $50.07, which was exercised on 11/21/2025, leaving 0 such derivative securities owned. The option had become exercisable in three equal annual installments beginning on March 1, 2017.